Last reviewed: July 3, 2026

Last updated: July 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic remains the most recognizable GLP-1 medication for weight loss, but supply constraints, insurance denials, and retail pricing often exceed $900 monthly out-of-pocket. Semaglutide—the active compound in Ozempic—is now available through licensed compounding pharmacies across all 50 states, offering patients the same clinical pathway at significantly lower cost. PlexusDx specializes in personalized GLP-1 therapy, helping patients find the right medication, dose, and genetic profile for sustainable weight management.

How Semaglutide Compares to Ozempic for Weight Loss

Ozempic and compounded semaglutide injections contain identical active pharmaceutical ingredients—they both activate GLP-1 receptors in the brain to reduce appetite, slow gastric emptying, and improve blood sugar control. Clinical trials show semaglutide users lose 10-15% of body weight over 68 weeks, with effects sustained as long as the medication continues. The primary difference is distribution: Ozempic is manufactured by Novo Nordisk and sold through traditional retail pharmacies, while compounded semaglutide is prepared by licensed 503A compounding pharmacies and delivered directly to patients.

PlexusDx sources semaglutide from licensed 503A compounding pharmacies that meet FDA sterility and potency standards. Users receive customizable dosing without the supply shortages that plagued Ozempic availability in 2023 and 2024. Monthly costs start at $149 for compounded semaglutide injection—less than one-fifth the typical Ozempic copay—with no insurance requirement, membership fee, or prior authorization delays.

Tirzepatide as a Dual-Action GLP-1 Alternative

Tirzepatide (brand name Zepbound, formerly Mounjaro) activates both GLP-1 and GIP receptors, a dual mechanism that produces stronger weight loss than semaglutide alone. In clinical trials, tirzepatide users lost 20-22% of body weight after 68 weeks—roughly 5-7 percentage points more than semaglutide monotherapy. This dual-pathway activation also improves blood pressure and cholesterol profiles beyond appetite suppression. PlexusDx offers compounded tirzepatide injections starting at $249 monthly, along with oral tirzepatide formulations for patients who prefer needle-free administration.

The choice between semaglutide and tirzepatide depends on individual genetics, metabolic history, and side-effect tolerance. Some patients respond optimally to single-pathway GLP-1 activation, while others achieve better results with dual GLP-1/GIP engagement. PlexusDx's Precision Peptide Genetic Test ($99 after first month) analyzes GIPR and GLP1R variants to predict which pathway your body responds to most effectively, removing guesswork from medication selection.

Oral vs. Injectable GLP-1 Medications for Weight Loss

Injectable semaglutide and tirzepatide deliver rapid onset and consistent absorption, with doses ranging from micrograms to full therapeutic levels depending on individual tolerance. Oral semaglutide and tirzepatide require higher doses because the gut absorbs only 1-2% of the compound, yet some patients prefer pills over weekly injections. PlexusDx offers all four formats: injectable semaglutide ($149/mo), oral semaglutide ($249/mo), injectable tirzepatide ($249/mo), and oral tirzepatide ($279/mo)—each at flat monthly rates regardless of dose escalation.

Your dose may need to go up. Your price won't. PlexusDx's pricing structure means patients can start at a conservative dose and titrate upward without monthly cost increases. Clinical studies show injectable formulations produce faster and more durable weight loss, but adherence rates are highest when patients choose the delivery method they'll actually use consistently. Oral medications work well for needle-averse individuals willing to take additional pills daily.

The Microdose GLP-1 Protocol for Tolerance and Sustainability

Some patients experience nausea, appetite loss beyond therapeutic goals, or gastrointestinal side effects at standard GLP-1 doses. PlexusDx's Microdose GLP-1 Protocol starts at just $129 monthly, offering sub-therapeutic doses designed to enhance natural satiety signals without the intensity of full-dose therapy. This approach works well for patients with prior adverse reactions, those sensitive to metabolic changes, or individuals seeking mild appetite support alongside lifestyle modifications rather than aggressive pharmaceutical intervention.

The microdose protocol typically produces 5-8% weight loss over 12-16 weeks—modest but meaningful for patients unable to tolerate higher doses. Combined with behavioral coaching and dietary tracking, microdosing creates a gentler entry point into GLP-1 therapy. If response remains limited after 8 weeks, PlexusDx can escalate to standard or dual-compound protocols without restarting enrollment or paying additional setup fees.

GLP-Squared: Dual-Compound Semaglutide and Tirzepatide Blend

For patients who respond partially to single-pathway therapy or plateau after initial weight loss, PlexusDx offers GLP-Squared—a compounded blend of semaglutide and tirzepatide in one injection. This combination activates GLP-1 and GIP simultaneously at lower individual doses than either agent alone, potentially reducing side effects while maximizing efficacy. Injectable GLP-Squared starts at $249 monthly, while the oral formulation begins at $369 monthly. Clinical evidence from combination GLP-1/GIP studies shows superior sustained weight loss and metabolic improvements compared to monotherapy after 12-24 weeks.

GLP-Squared appeals to patients experiencing plateaus—when weight loss stalls despite months of adherence to a single medication. The dual mechanism re-engages multiple appetite-regulating pathways, often producing an additional 3-5% weight loss in plateau-phase users. PlexusDx pharmacists assess candidacy and manage the transition with zero increase to monthly costs compared to single-agent therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide as safe and effective as brand-name Ozempic?

Yes. Compounded semaglutide contains identical active pharmaceutical ingredient and is prepared in licensed 503A compounding pharmacies under FDA quality standards for sterility, potency, and purity—identical to retail Ozempic. Clinical outcomes are equivalent when dose titration follows approved protocols. PlexusDx ensures all compounded medications meet pharmaceutical-grade specifications before dispensing.

How much weight can I expect to lose with semaglutide or tirzepatide?

Semaglutide users lose 10-15% of baseline body weight over 68 weeks in clinical trials. Tirzepatide users lose 20-22% over the same period. Individual results vary based on starting weight, adherence, diet quality, exercise, sleep, and genetic factors—which is why PlexusDx offers the Precision Peptide Genetic Test to predict your best medication match.

Can I use PlexusDx medications with insurance or FSA/HSA accounts?

PlexusDx medications require no insurance, but if you have HSA or FSA funds, both are eligible because compounded GLP-1 medications are prescribed by licensed physicians. PlexusDx also works with patients who have insurance to explore reimbursement pathways, though all pricing is the same whether claimed or paid out-of-pocket.

What are the most common side effects of GLP-1 therapy?

Nausea, vomiting, diarrhea, and constipation occur in 20-40% of users, especially during dose escalation, and resolve in most patients within 1-2 weeks. Rare but serious risks include pancreatitis, gallbladder disease, and thyroid complications—which is why PlexusDx requires baseline labs and physician oversight. Microdose protocols minimize side effects for sensitive individuals.

How does the Precision Peptide Genetic Test help with medication choice?

PlexusDx's Precision Peptide Genetic Test ($99 add-on) analyzes GLP1R, GIPR, FTO, and MC4R variants to identify which peptide pathways your genes respond to most effectively. Patients with certain GLP1R or GIPR variants show 30-40% greater weight loss on tirzepatide, while others respond optimally to semaglutide monotherapy—removing trial-and-error from therapy selection.

Related Reading

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves